JB Chemicals Analyst Meet Takeaways: ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
JB Chemicals and Pharmaceuticals Ltd. hosted an investor/analyst meet for the first time after KKR took the controlling stake in the company.
The focus of the management was clear on maintaining strong growth momentum coupled with profitability improvement.
India business would remain key priority with an expectation of 12-14% improvement in medical representative productivity.
Research and development initiatives would enhance to support increased filings in U.S. and strengthening of product portfolio across the businesses.
We remain positive considering ~45% of total revenues and ~60% of Ebitda contribution is from domestic formulations with strong growth visibility coupled with focus on improving productivity, portfolio expansion and cost optimisation.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.